Plain-English translation of NCT06464991 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new treatment called equecabtagene autoleucel (eque-cel), which is a type of immunotherapy that uses your own immune cells reprogrammed to fight multiple myeloma. The study compares this medication to standard chemotherapy drugs to see which works better for people whose myeloma has become resistant to lenalidomide, a common treatment.
Multiple myeloma is a serious blood cancer that many patients develop resistance to after initial treatments. This medication represents a newer approach using your body's own immune system, and researchers want to understand whether it offers better outcomes than older standard chemotherapy drugs for patients in this situation.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication eque-cel or standard chemotherapy drugs (a combination chosen by your doctor). The study lasts about 6 years and involves regular visits for blood tests, imaging scans, and safety monitoring. If you receive the new treatment, your doctors will carefully track how your immune cells respond and how well the medication works against your myeloma.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China